COVID-19 is associated with disseminated lung damage in patients, Dexamethasone can reduce lung injury caused by inflammation and there reduce the progression to respiratory failure and prevent death. This systematic review aimed to determine the benefits and safety of Dexamethasone in COVID-19 treatment. The study was performed by a comprehensive literature search which were published in several databases i.e., PubMed, Science Direct, VHL Regional Portal, and ClinicalTrials.gov within the search time of 28 November 2020. Inclusion criteria were articles on the study on COVID-19 patients who received Dexamethasone, observational and experimental studies on the outcomes use evaluation of Dexamethasone. Exclusion criteria are the articles that do not provide control in controlled studies and do not show clear research results on the use of Dexamethasone. An initial search from four databases by entering keywords resulted in 1,046 articles. After screening articles duplication we obtained 835 studies. Finally, 6 articles were obtained after we screened for the article that it can be obtained its full text and 5 articles joined in articles included in the meta-analysis. The analysis showed that Dexamethasone in Covid-19 patients could reduce the incidence of death within 28 days with RR of 0.78 (95% CI 0.57–0.97 P=0.13) compared with Methylprednisolone, Dexamethasone was compared without corticosteroids with RR 0.89 (95% CI 0.82-0.97 P=0.01). Dexamethasone also reduced mechanical ventilator use during treatment with RR 0.95 (95% CI = 0.86-1.05 P = 0.28) compared without corticosteroids. The conclusion from these results: the use of Dexamethasone can reduce the number of deaths in COVID-19 patients, especially severe and critically ill category patients.

Penyakit coronavirus 2019 (COVID-19) menimbulkan perhatian kesehatan yang besar saat ini, terutama untuk lanjut usia. Wabah pneumonia virus yang tidak diketahui dengan etiologinya pertama kali diperkenalkan di Wuhan, Cina pada 12 Desember 2019. Orang-orang dengan penyakit komorbid lebih beresiko menderita gejala yang parah apabila terkena virus corona. Penelitian ini bersifat deskriptif dengan menggunakan data retrospektif. Jumlah sampel yang memenuhi kriteria inklusi dan tidak memenuhi kriteria eksklusi sebesar 200 orang. Penelitian ini bertujuan untuk mengetahui karakteristik data demografi usia dan jenis kelamin pada komorbid pasien COVID-19 dan dapat menganalisis faktor resiko kasus terkonfirmasi COVID-19 dengan komorbid di Rumah Sakit Permata Cirebon. Hasil data demografi jenis kelamin pada pasien COVID-19 didominasi oleh laki-laki 1,93 kali dari jenis kelamin perempuan, data demografi usia pada pasien COVID-19 didominasi oleh kelompok usia kurang dari 60 tahun sebanyak 4,38 kali dari kelompok usia lebih dari 60 tahun, sedangkan faktor komorbid COVID-19 yang paling banyak adalah Penyakit Jantung yaitu 1,050 kali dari komorbid lainnya yaitu hipertensi, diabetes melitus, dan penyakit ginjal.